TriangleElacestrant + T-DXd (NCT07198724)
Elacestrant + T-DXd trial for HR-Positive, HER2-Low or Ultralow Metastatic Breast Cancer (NCT07198724). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with hormone receptor positive, HER2 low or HER2 ultralow metastatic breast cancer that has grown despite a CDK4/6 inhibitor and hormone therapy.
The idea: combine two drugs. Elacestrant is a pill that breaks down the estrogen receptor. Trastuzumab deruxtecan is an antibody drug conjugate that carries chemotherapy to cells with HER2 and is given by vein.
The study looks at safety and how well the combination works.
This phase 1 and 2 study plans 65 patients. At Dana-Farber Cancer Institute in Boston, Kristina Fanucci leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.